General Information

Posted 12 January 2004

Transgene: Mouse pronuclei (B6D2F1) were injected with a transgenic construct containing cDNA-encoding hAPP751 with Swedish double mutation (at 670/671 position) plus London mutationV717I (replaces a 600bp BglII-Spel fragment), regulated by the human Thy-1 promoter.

Promoter: Human Thy-1 promotor

Mouse Strain: Origin: C57B/6

Phenotype

Neuropathological Analysis:

2 fold overexpression of APP mRNA. APP22 mice show inflammatory and massive glial response. Aβ deposits, a diffuse type, are detected in neocortex and hippocampus of 18 month old mice, but not in 12 month old. APP22 mice show neuritic changes, dystrophic cholinergic fibers and hyperphosphorylated tau.

Behavioral:

No abnormal behavioral changes reported in APP14 mice.

Availability

Contact:
Matthias Staufenbiel
Novartis Pharma, Inc.,
S-386.809, CH-4002 Basel, Switzerland
Email: Matthias Staufenbiel

Patents: None

References

Primary:

Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997 Nov 25;94(24):13287-92. Abstract.